Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab +/- Tremelimumab with Chemotherapy in Advanced Urothelial Cancer (NILE)
NCT03682068Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2018
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of durvalumab and tremelimumab in urothelial carcinoma (UC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall Survival at 5 years. Started Sep 2018; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03682068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682068.